Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway
Regenxbio Inc. reported its Q1 2026 financial results, exiting the quarter with $150.5 million in cash, which is expected to fund operations into early 2027. The company announced positive Phase 3 trial results for its RGX-202 gene therapy for Duchenne and anticipates a $100 million milestone payment from AbbVie related to their partnered retinal treatment program. While the article highlights RGNX's potential, it also suggests that some AI stocks may offer higher returns in a shorter timeframe.
REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO Inc. (Nasdaq: RGNX) announced its participation in two upcoming investor conferences: the 2026 RBC Capital Markets Global Healthcare Conference on May 20th and the Stifel 2026 Virtual Ophthalmology Forum on May 26th. The company, focused on gene therapy for rare and retinal diseases, will conduct fireside chats at both events. Live webcasts and archived replays will be available on their website.
REGENXBIO Inc. (NASDAQ:RGNX) Q1 2026 Earnings Call Transcript
REGENXBIO Inc. (NASDAQ:RGNX) announced positive top-line data from its AFFINITY DUCHENNE pivotal trial for RGX-202, an investigational gene therapy for Duchenne muscular dystrophy, with high statistical significance in microdystrophin expression and functional improvement. The company plans for potential FDA accelerated approval in 2027 and highlighted the therapy's impressive safety profile and strong correlation between microdystrophin expression and clinical benefit. Experts on the call emphasized the significant unmet need for Duchenne patients, particularly older individuals and access to effective therapies, noting RGX-202's potential to differentiate in the market.
Biotech REGENXBIO lines up May investor talks in New York and online
REGENXBIO (Nasdaq: RGNX) announced its participation in two upcoming investor conferences in May 2026. The biotech company will hold a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference in New York on May 20 and another at the Stifel 2026 Virtual Ophthalmology Forum on May 26. Live webcasts and 30-day replays of these events will be available on REGENXBIO's investor relations website.
Regenxbio Inc earnings missed by $0.38, revenue fell short of estimates
Regenxbio Inc (NASDAQ: RGNX) reported a first-quarter EPS of $-1.72, missing the analyst estimate by $0.38. The company's revenue for the quarter was $6.39M, which was significantly lower than the consensus estimate of $25.8M. Despite the earnings miss, Regenxbio's stock has seen positive performance, rising 25.66% in the last three months and 16.20% in the last 12 months.
REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval
REGENXBIO announced positive topline and interim functional data from its AFFINITY DUCHENNE trial for RGX-202, an investigational gene therapy for Duchenne muscular dystrophy. The study met its primary endpoint, showing significant microdystrophin expression and functional improvements, leading the company to pursue accelerated FDA approval and a potential 2027 commercial launch. Despite the positive data, REGENXBIO's stock experienced a significant drop, possibly due to two serious adverse events reported and better efficacy in younger patients.
REGENXBIO to push for accelerated approval of DMD gene therapy
REGENXBIO plans to seek accelerated FDA approval for its Duchenne muscular dystrophy (DMD) gene therapy, RGX-202, following positive Phase III trial results that showed high microdystrophin expression and functional improvement. The therapy demonstrated a favorable safety profile and higher benefit compared to Sarepta’s Elevidys in microdystrophin expression. Despite promising trial data, the company's stock dropped after underwhelming Q1 earnings.
REGENXBIO Inc. Stock 12‑Month Price Target Cut to $28.25, Implies 181% Upside
Analysts have revised REGENXBIO Inc.'s average 12-month price target down from $29.25 to $28.25, suggesting a potential upside of 181% from its May 13 closing price. Despite the cut, the consensus rating from 12 analysts remains a "Buy," with 11 recommending "Buy" and 1 "Hold."
Regenxbio: Q1 Earnings Snapshot
Regenxbio Inc. (RGNX) reported a first-quarter loss of $90.1 million, or $1.72 per share, falling short of Wall Street expectations which anticipated a loss of $1.36 per share. The biotechnology company also missed revenue forecasts, posting $6.4 million against an expected $23.8 million. These figures were generated by Automated Insights using data from Zacks Investment Research.
RGX-202 success drives plans as REGENXBIO (NASDAQ: RGNX) burns cash
REGENXBIO (RGNX) reported a significant net loss of $90.1 million in Q1 2026 and reduced revenue, primarily due to the absence of prior-period major license revenue and lower ZOLGENSMA royalties. Despite financial setbacks, the company achieved a pivotal success with its Duchenne gene therapy RGX-202, meeting its primary endpoint with 93% of patients showing microdystrophin expression, supporting plans for accelerated approval and a potential 2027 commercial launch. REGENXBIO also anticipates a $100 million milestone payment from AbbVie in Q2 2026 and had a clinical hold lifted for its RGX-121 program.
REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202
REGENXBIO Inc. announced positive topline and interim functional data from its pivotal Phase III AFFINITY DUCHENNE® trial of RGX-202 for Duchenne Muscular Dystrophy. The study met its primary endpoint, with 93% of participants achieving significant microdystrophin expression, and demonstrated a strong correlation between microdystrophin expression and functional improvement. RGX-202 was well-tolerated, and the company plans to pursue accelerated approval for a potential commercial launch in 2027.
Investigation announced for Long-Term Investors in shares
An investigation has been announced for long-term investors in REGENXBIO Inc. (NASDAQ: RGNX) shares regarding potential breaches of fiduciary duties by the company's directors and officers. This follows a lawsuit alleging securities law violations related to REGENXBIO's RGX-111 gene therapy, which experienced a clinical hold and significant stock price decline after an adverse event. Investors affected are encouraged to contact the Shareholders Foundation for options.
REGENXBIO (RGNX) CMO 10b5-1 sale, still holding 232,617 shares
REGENXBIO Inc.'s Chief Medical Officer, Steve Pakola, sold 15,309 shares of common stock on May 11, 2026, at a weighted average price of $11.02 per share. This transaction was conducted under a Rule 10b5-1 trading plan. Following the sale, Pakola still directly holds 232,617 shares of RGNX.
Insider Sell Alert: Steve Pakola Sells Shares of Regenxbio Inc (RGNX)
Steve Pakola, Chief Medical Officer at Regenxbio Inc (RGNX), recently sold 15,309 shares of the company, bringing his total holdings to 232,617 shares. This sale contributes to a pattern of five insider sales and no insider purchases at Regenxbio over the past year. The stock is currently trading at $11.02, with a GF Value of $23.31, suggesting it might be a "Possible Value Trap."
Number of shareholders of REGENXBIO, Inc. – DUS:RB0
This article from TradingView provides information on REGENXBIO, Inc. (DUS:RB0), specifically focusing on its number of shareholders. The content appears to be a stub or a placeholder, as it lists financial data periods and value changes without providing the actual figures. It references market and reference data sources indicating it would typically present detailed financial information.
State Street (NASDAQ: RGNX) Files Schedule 13G for 5.3% Stake
State Street Corporation has filed a Schedule 13G, disclosing a beneficial ownership of 2,731,553 shares of REGENXBIO Inc. common stock, which represents 5.3% of the class. The filing specifies shared voting power over 2,666,105 shares and shared dispositive power over all 2,731,553 shares. This disclosure indicates a passive institutional investment by State Street and its affiliated entities, without sole voting or dispositive control.
Splicing Patent Eligibility: The Federal Circuit Restores § 101 Eligibility for Engineered Cells in 'REGENXBIO v. Sarepta'
The Federal Circuit reversed a summary judgment ruling that had invalidated patent claims related to engineered host cells in REGENXBIO Inc. v. Sarepta Therapeutics, Inc., restoring § 101 eligibility for these cells. This article by Rob Maier, an intellectual property and patent trial partner, discusses the background of the dispute, the Federal Circuit's reasoning, and the practical implications for patent strategy in the biologics field. Access to the full content requires a subscription to Law.com.
RGNX (NASDAQ: RGNX) director sells restricted shares under 10b5-1
A director at REGENXBIO Inc. (NASDAQ: RGNX), Stephen Pakola, reported the sale of 5,124 restricted shares on March 10, 2026, for $53,033.40 under a 10b5-1 plan. The Form 144 filing also noted 34,917 restricted stock units dated January 1, 2026. This transaction is considered a routine compliance filing, providing transparency regarding insider dispositions.
Earnings Preview: Regenxbio to Report Financial Results Pre-market on May 14
Regenxbio (NASDAQ:RGNX) is scheduled to announce its financial results pre-market on Tuesday, May 14. Analysts expect a GAAP EPS of -$0.93 and revenue of $40.54 million. Comparing this to prior quarters and year-over-year performance will be key to understanding the company's financial health.
REGENXBIO brings Duchenne gene therapy data back to ASGCT
REGENXBIO announced its participation in the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, where it will present data on its Duchenne muscular dystrophy gene therapy program, RGX-202, and advancements in its NAVXpress manufacturing platform. The company will also highlight its progress in next-generation gene therapies for rare and retinal diseases through various poster presentations. This news led to a significant increase in REGENXBIO's stock price, demonstrating investor interest in its pipeline and technology.
REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy
REGENXBIO Inc. will host a webcast on Thursday, May 14, 2026, at 8:00 a.m. ET to discuss topline results from the pivotal trial of RGX-202, their investigational gene therapy for Duchenne muscular dystrophy. The webcast will feature leading Duchenne physicians. The company will also report financial results and operational highlights for the first quarter ended March 31, 2026, ahead of the webcast.
Duchenne gene therapy trial results are due in REGENXBIO webcast
REGENXBIO (RGNX) will host a webcast on May 14, 2026, to announce topline results from the pivotal trial of RGX-202, an investigational gene therapy for Duchenne muscular dystrophy. The company will also release its first-quarter 2026 financial results on the same day. The webcast will include presentations from leading Duchenne physicians.
Nancy Pelosi Stock Tracker Highlights Claude's Pharma Earnings Play: 'Will Be Interesting To See How This One Plays Out'
The Nancy Pelosi Stock Tracker highlighted an AI-powered portfolio, "The Claude Portfolio," which invested in Denali Therapeutics (NASDAQ: DNLI) ahead of its Q1 2026 earnings report. Claude AI allocated 4.82% of its fund to Denali, viewing it as a high-risk-high-reward earnings play, anticipating insights into the commercial launch of its neurological Hunter syndrome treatment, AVLAYAH, and Wall Street potentially undervaluing the stock. Despite acknowledging risks like cash burn and manufacturing challenges, Claude projected a 32% upside and emphasized Denali's competitive advantage with no current FDA-approved competitors for AVLAYAH.
Morgan Stanley cuts Regenxbio stock price target on model updates
Morgan Stanley has reduced its price target for Regenxbio Inc. (NASDAQ:RGNX) to $17 from $18 but maintained an Overweight rating, citing model updates after the company's fourth-quarter 2025 results. Despite the cut, the new target still implies a nearly 100% upside from the current stock price. Regenxbio ended fiscal year 2025 with $240.9 million in cash and marketable securities and expects this to fund operations into early 2027, potentially extending later with milestone payments.
Duchenne Muscular Dystrophy Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Vertex Pharma, Bioleaders Corp., Wave Life Sciences, REGENXBIO
A new report by DelveInsight titled "Duchenne Muscular Dystrophy Pipeline Insight, 2026" details the active development of over 75 Duchenne Muscular Dystrophy (DMD) treatment therapies by more than 75 companies globally. The report provides a comprehensive analysis of the clinical trial landscape, therapy innovations, and FDA updates related to Duchenne Muscular Dystrophy. Recent developments highlighted include progress in clinical trials by companies like Precision BioSciences, Solid Biosciences, and REGENXBIO, as well as regulatory milestones such as Orphan Drug Designation and Breakthrough Therapy designation for new DMD treatments.
REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of "Moderate Buy" by Brokerages
REGENXBIO Inc. (NASDAQ:RGNX) has received a "Moderate Buy" consensus rating from brokerages, with an average 1-year price target of $27.50. This comes despite the company missing expectations in its latest quarter, reporting an EPS of ($1.30) against an anticipated ($1.01) and revenue of $30.34 million versus $45.48 million expected. Institutional investors hold a significant 88.08% of the stock, while insiders own 12.79%, with one insider recently selling 5,124 shares.
Federal Circuit Rejects Biotech Company’s Rehearing Bid For DNA Patent Claims
The Federal Circuit U.S. Court of Appeals has denied a gene therapy product maker's petition for rehearing en banc, upholding a previous panel's decision. This means the court's earlier finding that a district judge erred in concluding a patent's claims for genetically engineered cultured host cells were directed to a natural phenomenon will stand. The decision leaves a Delaware federal court ruling in question regarding the patentability of certain DNA-related claims.
Full Fed. Circ. Passes On Sarepta's Patent Rehearing Bid
The Federal Circuit has rejected Sarepta Therapeutics Inc.'s request for a rehearing regarding a University of Pennsylvania gene therapy patent. This decision follows a previous panel ruling that revived the patent, which is licensed by a clinical-stage company. The full article can be accessed by registering for a free trial or logging in for existing subscribers.
(RGNX) Movement Within Algorithmic Entry Frameworks
This article from Stock Traders Daily analyzes Regenxbio Inc. (NASDAQ: RGNX) using AI models, indicating a near-term neutral sentiment amidst mid and long-term strength. It highlights an exceptional 132.5:1 risk-reward setup targeting a 31.2% gain against 0.2% risk and outlines three distinct trading strategies: Position, Momentum Breakout, and Risk Hedging. The analysis also provides multi-timeframe signal analysis with support and resistance levels.
REGENXBIO (NASDAQ:RGNX) Shares Pass Below 200-Day Moving Average - Should You Sell?
REGENXBIO (NASDAQ:RGNX) shares have fallen below their 200-day moving average, trading at $9.11 against an average of $11.31, following disappointing quarterly results with a significant EPS and revenue miss. Analyst ratings are mixed, with a "Moderate Buy" consensus but several firms have cut price targets or downgraded the stock due to underperformance and negative financial metrics. Insider trading activity shows a recent sale by an insider, while institutional investors have adjusted their positions in the company.
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit
The Rosen Law Firm is reminding investors of REGENXBIO, Inc. (NASDAQ: RGNX) who purchased securities between February 9, 2022, and January 27, 2026, about the April 14, 2026, deadline to seek lead plaintiff status in a securities fraud lawsuit. The lawsuit alleges that REGENXBIO made false and misleading statements about the efficacy and safety of its RGX-111 gene therapy trial. Investors who suffered damages can join the class action to potentially seek compensation.
REGENXBIO (NasdaqGS:RGNX) Stock Forecast & Analyst Predictions
REGENXBIO is forecasted to grow earnings by 50.5% and revenue by 29.1% annually, despite future unprofitability. Analysts have recently trimmed price targets for RGNX due to regulatory risks, clinical execution, and updated timelines for key gene therapy programs, with the consensus price target decreasing to US$28.45. The company's future hinges on upcoming regulatory updates and pivotal readouts in its gene therapy pipeline, particularly for Duchenne muscular dystrophy and wet age-related macular degeneration.
[ARS] REGENXBIO Inc. SEC Filing
This article announces an ARS SEC filing by REGENXBIO Inc. (RGNX) dated April 14, 2026, accessible as a PDF document. It provides an overview of the filing's low impact and neutral sentiment, along with recent news and other SEC filings related to the company. The company's stock data, including market cap and industry, are also listed.
Lifshitz Law Firm Investigating PayPal, Enphase Energy, and REGENXBIO
The Lifshitz Law Firm is conducting investigations into potential securities law violations and breaches of fiduciary duties at PayPal Holdings, Inc., Enphase Energy, Inc., and REGENXBIO Inc. These investigations could result in shareholder lawsuits and regulatory actions, potentially impacting the companies' stock and public reputation. The firm announced these investigations on April 15, 2026, examining various issues to determine if actionable claims exist on behalf of shareholders.
RGNX DEADLINE - FINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts REGENXBIO Inc. Investors to Participate in the Class Action Lawsuit Today
Bronstein, Gewirtz & Grossman, LLC reminds investors of REGENXBIO Inc. (NASDAQ:RGNX) about the ongoing class action lawsuit. The lawsuit alleges that REGENXBIO made misleading statements regarding its gene therapy RGX‑111 for Hurler syndrome, overstating its efficacy and safety. Investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026, have until April 14, 2026, to request to be appointed lead plaintiff.
REGENXBIO (RGNX) 2026 proxy details director votes, auditor, and stock option exchanges
REGENXBIO Inc. (RGNX) has released details for its 2026 annual stockholders' meeting, where key agenda items include the election of three Class II directors, ratification of PricewaterhouseCoopers LLP as the independent auditor, and an advisory vote on 2025 executive compensation. Notably, stockholders will also vote on two separate stock option exchange programs for both non-executive and executive employees to address underwater options, aiming to incentivize and retain talent. The proxy statement also highlights the company's clinical progress in gene therapy and a strong financial position, ending 2025 with $240.9 million in cash.
RGNX Deadline Today: Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Rosen Law Firm has announced a class action lawsuit against REGENXBIO, Inc. (NASDAQ: RGNX) on behalf of investors who purchased securities between February 9, 2022, and January 27, 2026. The lawsuit alleges that REGENXBIO misled investors about the efficacy and safety of its product candidate RGX-111, a gene therapy for Hurler syndrome. Stockholders with significant losses are urged to contact the firm by the April 14, 2026, lead plaintiff deadline to learn about their rights.
RGNX Deadline Today: Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
The Rosen Law Firm has announced a class action lawsuit against REGENXBIO, Inc. (NASDAQ: RGNX) on behalf of investors who purchased securities between February 9, 2022, and January 27, 2026. The lawsuit alleges REGENXBIO misled investors about the efficacy and safety of its product candidate RGX-111, causing investors to suffer losses. Stockholders with significant losses are urged to contact the firm by the April 14, 2026, deadline to potentially serve as lead plaintiff.
RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit
The Rosen Law Firm reminds investors who purchased REGENXBIO, Inc. (NASDAQ: RGNX) securities between February 9, 2022, and January 27, 2026, that today, April 14, 2026, is the lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that REGENXBIO made false and misleading statements regarding the efficacy and safety of its RGX-111 gene therapy trial for Hurler syndrome. Investors can join the class action to seek compensation for alleged damages.
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of the Securities Class Action Lawsuit Deadline on April 14, 2026
Faruqi & Faruqi, LLP is investigating potential claims against REGENXBIO Inc. (NASDAQ: RGNX) and reminds investors of the April 14, 2026, deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that REGENXBIO made false and misleading statements and/or failed to disclose material adverse facts regarding the efficacy and safety of its RGX-111 trial study, leading to a significant stock price drop following an FDA clinical hold on its investigational gene therapies RGX-111 and RGX-121. Investors with substantial losses are encouraged to contact Faruqi & Faruqi.
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of the Securities Class Action Lawsuit Deadline on April 14, 2026
Faruqi & Faruqi, LLP is reminding REGENXBIO (RGNX) investors of the securities class action lawsuit deadline on April 14, 2026. The lawsuit alleges that REGENXBIO made misleading statements regarding the efficacy and safety of its RGX-111 trial study, leading to a significant stock price drop after the FDA placed a clinical hold on RGX-111 and RGX-121 due to a reported adverse event. Investors who acquired REGENXBIO securities between February 9, 2022, and January 27, 2026, are encouraged to contact the firm to discuss their legal rights.
Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit against REGENXBIO, Inc. on behalf of investors who purchased securities between February 9, 2022, and January 27, 2026. The lawsuit alleges that REGENXBIO made false and misleading statements regarding its RGX-111 gene therapy trial, which saw a clinical hold placed by the FDA after a participant developed an intraventricular CNS tumor, leading to a nearly 18% drop in the company's stock price. Investors have until April 14, 2026, to file a lead plaintiff motion.
RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit -- The Gross Law Firm
The Gross Law Firm has issued a shareholder alert for investors of REGENXBIO Inc. (NASDAQ: RGNX), encouraging those who suffered losses to seek lead plaintiff status in a securities class action lawsuit. The lawsuit alleges that REGENXBIO made false and misleading statements about the efficacy and safety of its gene therapy RGX-111, particularly concerning its Phase I/II study, which led to a significant stock price drop after the FDA placed a clinical hold on the therapy. Shareholders who purchased RGNX shares between February 9, 2022, and January 27, 2026, have until April 14, 2026, to register for the class action.
Levi & Korsinsky, LLP: RGNX Disclosure Timeline Reveals Pattern of Alleged Investor Harm
Levi & Korsinsky, LLP is encouraging investors who suffered losses in REGENXBIO, Inc. (NASDAQ: RGNX) to contact their firm, alleging that the company's disclosure timeline reveals a pattern of investor harm. The lawsuit contends that RGNX securities holders who purchased between February 9, 2022, and January 27, 2026, may be entitled to recover damages due to the company's alleged concealment of material safety risks related to its gene therapy RGX-111, culminating in an FDA clinical hold. Investors must act by April 14, 2026, to apply for lead plaintiff.
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has announced a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) and its officers, alleging violations of federal securities laws. The lawsuit claims that REGENXBIO made false and misleading statements regarding its RGX-111 gene therapy for Hurler syndrome between February 9, 2022, and January 27, 2026. Investors who suffered losses are encouraged to join the case before the lead plaintiff deadline of April 14, 2026.
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is reminding investors of REGENXBIO Inc. (NASDAQ: RGNX) about a class action lawsuit for alleged securities fraud. The lawsuit claims that Regenxbio made misleading statements regarding its product candidate RGX-111, concealing negative efficacy and safety data, which led to investor losses. Investors who purchased securities between February 9, 2022, and January 27, 2026, are encouraged to contact the firm by April 14, 2026.
Rosen Law Firm Encourages REGENXBIO Investors to Secure Counsel Before Deadline
The Rosen Law Firm is advising investors who purchased REGENXBIO, Inc. (NASDAQ: RGNX) securities between February 9, 2022, and January 27, 2026, that they have until April 14, 2026, to join a securities class action lawsuit. The lawsuit alleges that REGENXBIO disseminated misleading information regarding the efficacy and safety of its RGX-111 trial study. This class action aims to recover damages for investors who suffered losses exceeding $100,000 due to the alleged misconduct.
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is reminding investors of a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) for alleged securities fraud violations. The lawsuit claims that Regenxbio made false and misleading statements regarding its product candidate RGX-111, concealing negative efficacy and safety data, which led to investor damages. Investors who purchased securities during the Class Period (February 9, 2022, to January 27, 2026) are encouraged to contact the firm to participate before April 14, 2026.
REGENXBIO DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages REGENXBIO, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action - RGNX
The Rosen Law Firm is reminding investors of REGENXBIO, Inc. (NASDAQ: RGNX) who suffered significant losses to secure legal counsel before the April 14, 2026 deadline for a securities class action lawsuit. The lawsuit alleges that REGENXBIO made false and misleading statements regarding its product candidate RGX-111, a gene therapy for Hurler syndrome, by overstating its efficacy and safety. Investors who purchased RGNX securities between February 9, 2022, and January 27, 2026, are encouraged to join the class action to potentially recover their damages.
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) and its officers, alleging violations of federal securities laws. The lawsuit claims that REGENXBIO made false and misleading statements regarding the development and commercialization of its gene therapy RGX‑111 for Hurler syndrome. Investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026, are encouraged to join the case, with a lead plaintiff deadline of April 14, 2026.
